Phathom Pharmaceuticals' (PHAT) shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.
Two analysts polled by Capital IQ projected a loss of $1.47 per share.
Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.
Analysts surveyed by Capital IQ expect $12.4 million.
"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023," according to the company.
Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.
Price: 17.41, Change: -0.59, Percent Change: -3.31
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。